| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S13513 R52199 |
Fitton - Calcium blockers (Controls unexposed, disease free), 2020 | Low birth weight (<2500 g) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified |
1.24 [0.55;2.78] excluded (control group) |
26/167 11,051/250,693 | 11,077 | 167 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14422 R57251 |
Fitton - Calcium blockers (Controls unexposed, sick), 2020 | Low birth weight (<2500 g) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 1.66 [1.09;2.54] C | 26/167 797/7,971 | 823 | 167 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13387 R52259 |
Mito - Amlodipine, 2019 | Low birth weight (<2500 g) | at least 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication | 0.54 [0.26;1.15] C | 12/48 49/129 | 61 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13449 R51811 |
Su - Calcium blockers (Controls unexposed, disease free), 2013 | Low birth weight (< 2,500 gm) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication |
2.19 [1.50;3.20] C excluded (control group) |
32/303 418/8,181 | 450 | 303 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13443 R51793 |
Su - Calcium blockers (Controls unexposed, sick), 2013 | Low birth weight (< 2,500 gm) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Indications Antihypertensive: Only chronic hypertension indication | 1.50 [0.97;2.33] | 32/303 76/1,006 | 108 | 303 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13969 R54754 |
Parazzini - Nifedipine, 1998 | Birthweight < 2500 g | 2nd and/or 3rd trimester | randomized controlled trial | unexposed, sick | Adjustment: Randomisation Indications Antihypertensive: All hypertensions, any indications or not specified | 1.09 [0.64;1.87] C | 40/129 37/127 | 77 | 129 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 1.20 [0.80;1.79] | 1,069 | 647 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls unexposed, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 13449, 13513